TrialFuture oncology (London, England)2019

ATLANTIS: a Phase III study of lurbinectedin/doxorubicin versus topotecan or cyclophosphamide/doxorubicin/vincristine in patients with small-cell lung cancer who have failed one prior platinum-containing line.

Anna F Farago et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.